Does Coffee Lower the Risk of Endometrial Cancer?

Article

Drinking coffee multiple times a day may decrease the risk of endometrial cancer in women, according to a new study.

Women who drank three cups of coffee per day had a lower risk of endometrial cancer. Photo © topseller/Shutterstock.com.

Drinking coffee multiple times a day may decrease the risk of endometrial cancer in women, according to a new study. Using dietary questionnaire results from three prospective studies on 84 different foods, the authors found that coffee intake was inversely associated with endometrial cancer risk.

In one of the studies, women who drank three cups of coffee per day-about 750 grams-had a 19% lower risk of endometrial cancer compared with women who drank less than one cup of coffee per day. Data from a different study cohort found that those who drank four cups of coffee per day-about 1,000 grams-had an 18% lower risk of endometrial cancer compared with those who did not drink coffee.

The results were published in Cancer Epidemiology, Biomarkers & Prevention.

Melissa A. Merritt, PhD, a statistician at the School of Public Health at Imperial College London in the United Kingdom, and colleagues assessed whether 84 nutrients and foods could be linked to endometrial cancer risk, using dietary questionnaires completed by 301,107 women who were between the ages of 25 and 70 at enrollment in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Of these women, 1,303 developed endometrial cancer.

From the EPIC study data, 10 foods and nutrients were found to have some association with a risk of endometrial cancer. An increased risk was associated with butter, yogurt, potatoes, and carbohydrates, while a decreased risk was associated with cheese, coffee, cream desserts, total fat, monounsaturated fat, and phosphorus.

The links between these foods and endometrial cancer risk were then further validated using a cohort of women who were part of the Nurses’ Health Study (NHS) and NHS II, from the Brigham and Women’s Hospital and Harvard School of Public Health, respectively. A total of 1,531 cases of endometrial cancer were reported from this cohort.

Only the links with butter and coffee were validated in the NHS cohort. Coffee has previously been linked to a decreased risk of endometrial cancer in both an NHS study and two prior meta-analyses.

It is not clear which components of coffee may be beneficial. One hypothesis is that coffee may be related to decreased C-peptide levels, a marker of reduced insulin secretion, which may lower exposure to estrogen and therefore obesity, said the authors in their discussion. Other studies have shown that increased intake of both caffeine and caffeine-containing coffee results in increased adiponectin levels, which is associated with lower insulin sensitivity and a decrease in estrogen levels. But, non-caffeine coffee components have also been implicated in cancer risk reduction.

“Coffee intake is worth investigating further to see if coffee can be used for the prevention of endometrial cancer. However, before clinical recommendations can be made, further studies are needed to evaluate this question in other studies and to try to isolate the components of coffee that may be responsible for any influence on endometrial cancer,” said Merritt in a statement.

Related Videos
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Pembrolizumab combined with carboplatin and paclitaxel resulted in response rates in patients with recurrent endometrial cancer.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Related Content